Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Arrowhead Pharmaceuticals stock

ARWR
US04280A1007
A2AGYB

Price

26.03
Today +/-
-0.11
Today %
-0.46 %

Arrowhead Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Arrowhead Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Arrowhead Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Arrowhead Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Arrowhead Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Arrowhead Pharmaceuticals Stock Price History

DateArrowhead Pharmaceuticals Price
11/29/202426.03 undefined
11/27/202426.15 undefined
11/26/202421.05 undefined
11/25/202418.79 undefined
11/22/202418.54 undefined
11/21/202418.28 undefined
11/20/202418.71 undefined
11/19/202418.60 undefined
11/18/202419.02 undefined
11/15/202418.57 undefined
11/14/202421.41 undefined
11/13/202421.63 undefined
11/12/202421.51 undefined
11/11/202421.97 undefined
11/8/202421.89 undefined
11/7/202421.39 undefined
11/6/202421.34 undefined
11/5/202420.57 undefined
11/4/202420.06 undefined
11/1/202419.49 undefined

Arrowhead Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Arrowhead Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Arrowhead Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Arrowhead Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Arrowhead Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Arrowhead Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Arrowhead Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Arrowhead Pharmaceuticals’s growth potential.

Arrowhead Pharmaceuticals Revenue, EBIT and net profit per share

DateArrowhead Pharmaceuticals RevenueArrowhead Pharmaceuticals EBITArrowhead Pharmaceuticals Net Income
2030e2.02 B undefined0 undefined1.38 B undefined
2029e1.42 B undefined746.07 M undefined713.6 M undefined
2028e830.55 M undefined189.76 M undefined213.99 M undefined
2027e471.8 M undefined-396.89 M undefined-45.33 M undefined
2026e244.95 M undefined-506.21 M undefined-471.26 M undefined
2025e153.59 M undefined-541.43 M undefined-535.65 M undefined
2024e76.43 M undefined-559.32 M undefined-600.67 M undefined
2023240.7 M undefined-205 M undefined-205.3 M undefined
2022243.2 M undefined-178.5 M undefined-176.1 M undefined
2021138.3 M undefined-149 M undefined-140.8 M undefined
202088 M undefined-93.2 M undefined-84.6 M undefined
2019168.8 M undefined61.2 M undefined68 M undefined
201816.1 M undefined-55.9 M undefined-54.5 M undefined
201731.4 M undefined-37 M undefined-34.4 M undefined
2016200,000 undefined-79.6 M undefined-81.7 M undefined
2015400,000 undefined-96 M undefined-91.9 M undefined
2014200,000 undefined-51.1 M undefined-58.6 M undefined
2013300,000 undefined-23.3 M undefined-31.1 M undefined
2012100,000 undefined-21.1 M undefined-21.1 M undefined
2011300,000 undefined-9.8 M undefined-3.1 M undefined
20100 undefined-5.8 M undefined-5.8 M undefined
20093.8 M undefined-19.6 M undefined-19.3 M undefined
20081.3 M undefined-35 M undefined-27.1 M undefined
20071.2 M undefined-37.1 M undefined-29.9 M undefined
2006500,000 undefined-18.2 M undefined-19 M undefined
2005600,000 undefined-7.4 M undefined-6.9 M undefined
2004200,000 undefined-2.2 M undefined-2.5 M undefined

Arrowhead Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19911992199319961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
0000000000000000000000000.030.020.170.090.140.240.240.080.150.240.470.831.422.02
----------------200.00---------48.39950.00-47.6256.8276.09-1.23-68.33101.3259.4893.0376.2271.5742.13
--------------------------------------
00000000000000000000000000000000000000
00-000000000-0-0.01-0.02-0.03-0.03-0.02-0.01-0-0.02-0.03-0.06-0.09-0.08-0.03-0.050.07-0.08-0.14-0.18-0.21-0.6-0.54-0.47-0.050.210.711.38
------------200.00216.6752.63-6.90-29.63-73.68-40.00600.0047.6287.1056.90-10.99-58.0258.82-225.93-223.5366.6725.7116.48192.68-10.83-11.96-90.45-573.33234.7493.83
000000000001.11.93.23.63.94.56.47.211.12446.957.461.173.983.698.6100.7103.7105.4106.80000000
--------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Arrowhead Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Arrowhead Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1991199219931996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                             
002.700000001.4922.52824.110.126.88.13.528.1154.298.885.465.676.5258.7315.5367.8376.4395.7
000.1000000000.1000.30.10.10.1000.1000.10.10.30.70.810.31.40
00000000000000.10000.81.62.500000000000
00600700000000000000000000000000000
00.10.100000000.20.40.20.70.90.40.30.30.10.60.60.64.15.12.31.95.96.16.627.523.8
00.13.50.70000001.69.522.728.825.310.62.489.86.628.8154.8102.990.66878.7265.3322.4384.7405.3419.5
0.10.10.50.10.10.10.100000.91.11.30.51.20.50.104.93.53.94.515.415.513.923.24766168.6335.6
0000000000000002.42.2220.31.723.1000044.2137.5245.6105.90
0000000000000000002.3000000000000
0000.100000001.13.33.42.92.82.421.74.83.2124.822.220.518.817.115.413.71210.3
0.10.30.4000000000.41.8100000000000000000
000000000000.10.10.21.10.30.10000000.10.10.10.10.30.30.20.2
0.20.40.90.20.10.10.100002.56.35.94.56.75.24.16108.42829.337.736.132.884.6200.2325.6286.7346.1
0.20.54.40.90.10.10.10001.6122934.729.817.37.612.115.816.637.2182.8132.2128.3104.1111.5349.9522.6710.3692765.6
                                                             
0000000000000000100100100100100100200200200200200200200200200
000.010.010.010.010.010.010.010.0100.010.040.060.080.10.110.120.130.140.190.390.430.490.510.580.660.971.051.221.3
-0.2-0.9-3.3-8.6-9.4-9.6-9-9.2-9.4-9.6-0.1-2.6-9.2-28.5-58.4-85.5-105-110.7-113.9-135-166.1-224.8-316.7-398.4-432.8-487.3-419.3-503.8-644.7-820.8-1,026
00000000000-0.2-0.7000000000-0.1000-0.40-0.1-0.1-3.2
0000000000000000000000000000000
00.12.8-1.8-2.6-2.8-1-1.2-1.3-1.51.49.426.130.626.312.34.99.112.81027.5166.5110.395.681.495.8244.6461.8408.8398.5271.4
00.20.61.11.11.40.20.20.20.30.10.50.50.81.31.310.70.60.91.22.6512.24.12.87.66.89.52.935.9
000.10.20.20.40.30.50.60.700.10.40.91.41.60.60.71.11.91.54.79.28.68911.514.52661.968.3
000.10.30.300000000.100.1002.40.92.34.84.31.54.76.50.47819.3111.174.11.3
0020080080050050050050060000000005000000000000000
0000.30.30.500000001.200.80.7000.31.20.30.20.20.20.200000
00.212.72.72.811.21.31.60.10.612.92.83.72.34.32.65.48.711.915.925.718.812.497.140.6146.6138.9105.5
0.10.10.40000000000000.70.500.62.11.10.80.52.52.32.100000
0000000000000000000000000000000
000000000000000.50.5000.10.31.84.26.252.11.98.720154.8134.8372.9
0.10.10.4000000000000.51.20.500.72.42.956.77.54.448.720154.8134.8372.9
0.10.31.42.72.72.811.21.31.60.10.612.93.34.92.84.33.37.811.616.922.633.223.216.4105.860.6301.4273.7478.4
0.10.44.20.90.1000-00.11.51027.133.529.617.27.713.416.117.839.1183.4132.9128.8104.6112.2350.4522.4710.2672.2749.8
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Arrowhead Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Arrowhead Pharmaceuticals's financial health and stability.

Assets

Arrowhead Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Arrowhead Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Arrowhead Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Arrowhead Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1991199219931996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
00-200000000-2-6-19-29-27-19-7-3-22-31-58-91-81-34-5468-84-140-176-209
000000000000001110011123444581012
0000000000000000000000000000000
000000000000010000000535-1-587-60226-98-51
000000000000-325-161061222301914162587153249172
0000000000000000000000000000000
0000000000000000000000000000000
00-200000000-2-9-14-23-27-15-7-5-15-19-35-65-64-23-47173-95171-136-153
000000000000000000000-1-12-3-7-1-12-12-23-52-176
000000000000200-20000-9-361413-48-7-47-240-141-5-96
000000000000300-10000-9-342617-40-6-35-228-1184780
0000000000000000000000000000000
00000000000000001000000000-2000250
0040000000192020157212411441850561260682571153
00500000001920202016612610441850551260662571165253
00000000000000592010000000000600
0000000000000000000000000000000
002000000017135-4-14-840-415113-514-605191-7840-762
-0.2-0.2-2.40000-0.1-0.1-0.1-0.2-3-9.9-15.7-24.7-28.3-15.3-7.7-5.4-15.8-19.3-37.1-77.7-68.3-31.8-48.6161-107.4147.6-188.9-330.6
0000000000000000000000000000000

Arrowhead Pharmaceuticals stock margins

The Arrowhead Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Arrowhead Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Arrowhead Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Arrowhead Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Arrowhead Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Arrowhead Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Arrowhead Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Arrowhead Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Arrowhead Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Arrowhead Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Arrowhead Pharmaceuticals Margin History

Arrowhead Pharmaceuticals Gross marginArrowhead Pharmaceuticals Profit marginArrowhead Pharmaceuticals EBIT marginArrowhead Pharmaceuticals Profit margin
2030e0 %0 %68.29 %
2029e0 %52.39 %50.11 %
2028e0 %22.85 %25.76 %
2027e0 %-84.12 %-9.61 %
2026e0 %-206.66 %-192.39 %
2025e0 %-352.52 %-348.75 %
2024e0 %-731.79 %-785.9 %
20230 %-85.17 %-85.29 %
20220 %-73.4 %-72.41 %
20210 %-107.74 %-101.81 %
20200 %-105.91 %-96.14 %
20190 %36.26 %40.28 %
20180 %-347.2 %-338.51 %
20170 %-117.83 %-109.55 %
20160 %-39,800 %-40,850 %
20150 %-24,000 %-22,975 %
20140 %-25,550 %-29,300 %
20130 %-7,766.67 %-10,366.67 %
20120 %-21,100 %-21,100 %
20110 %-3,266.67 %-1,033.33 %
20100 %0 %0 %
20090 %-515.79 %-507.89 %
20080 %-2,692.31 %-2,084.62 %
20070 %-3,091.67 %-2,491.67 %
20060 %-3,640 %-3,800 %
20050 %-1,233.33 %-1,150 %
20040 %-1,100 %-1,250 %

Arrowhead Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Arrowhead Pharmaceuticals earnings per share therefore indicates how much revenue Arrowhead Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Arrowhead Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Arrowhead Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Arrowhead Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Arrowhead Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Arrowhead Pharmaceuticals Revenue, EBIT and net profit per share

DateArrowhead Pharmaceuticals Sales per ShareArrowhead Pharmaceuticals EBIT per shareArrowhead Pharmaceuticals Earnings per Share
2030e16.28 undefined0 undefined11.12 undefined
2029e11.45 undefined0 undefined5.74 undefined
2028e6.68 undefined0 undefined1.72 undefined
2027e3.8 undefined0 undefined-0.36 undefined
2026e1.97 undefined0 undefined-3.79 undefined
2025e1.24 undefined0 undefined-4.31 undefined
2024e0.61 undefined0 undefined-4.83 undefined
20232.25 undefined-1.92 undefined-1.92 undefined
20222.31 undefined-1.69 undefined-1.67 undefined
20211.33 undefined-1.44 undefined-1.36 undefined
20200.87 undefined-0.93 undefined-0.84 undefined
20191.71 undefined0.62 undefined0.69 undefined
20180.19 undefined-0.67 undefined-0.65 undefined
20170.42 undefined-0.5 undefined-0.47 undefined
20160 undefined-1.3 undefined-1.34 undefined
20150.01 undefined-1.67 undefined-1.6 undefined
20140 undefined-1.09 undefined-1.25 undefined
20130.01 undefined-0.97 undefined-1.3 undefined
20120.01 undefined-1.9 undefined-1.9 undefined
20110.04 undefined-1.36 undefined-0.43 undefined
20100 undefined-0.91 undefined-0.91 undefined
20090.84 undefined-4.36 undefined-4.29 undefined
20080.33 undefined-8.97 undefined-6.95 undefined
20070.33 undefined-10.31 undefined-8.31 undefined
20060.16 undefined-5.69 undefined-5.94 undefined
20050.32 undefined-3.89 undefined-3.63 undefined
20040.18 undefined-2 undefined-2.27 undefined

Arrowhead Pharmaceuticals business model

Arrowhead Pharmaceuticals Inc is a biotechnology company that develops and commercializes RNA-based therapeutics. The company is headquartered in Pasadena, California and was founded in 2007. Arrowhead's history began when a group of scientists at the University of Texas came together to work on the development of RNA-based therapeutics. In 2007, Arrowhead was established and the company's patented TRiM™ (Targeted RNAi Molecules) technology was developed to specifically overcome barriers in RNAi-based therapeutics. The company is divided into several divisions, including Hepatitis B, cardiovascular, metabolic disorders, and oncology. Arrowhead has developed a range of RNAi-based investigational products, including ARC-520, which is being developed for the treatment of Hepatitis B and is currently in clinical trials. ARC-520 is designed to inhibit the formation and release of viral particles in liver cells, thereby halting the progression of the disease. Arrowhead has also developed products for the treatment of life-threatening diseases such as Alpha-1 Antitrypsin Deficiency (AAT) and hypertriglyceridemic pancreatitis (HTG). The treatments offered by Arrowhead aim to utilize RNA in disease treatment where other methods have failed. Arrowhead Pharmaceuticals Inc's business model is based on the discovery, development, and commercialization of RNAi-based therapeutics. The company collaborates with partners to accelerate the development and commercialization of its products. Arrowhead has a strategic partnership with Johnson & Johnson Pharmaceuticals Research & Development, LLC. Arrowhead Pharmaceuticals Inc is listed on the NASDAQ stock exchange under the ticker symbol ARWR. The company employs approximately 150 employees, including scientists, researchers, and specialists specialized in RNA biology. Recently, Arrowhead Pharmaceuticals Inc partnered with Takeda Pharmaceutical Co. Ltd. to develop RNAi-based therapeutics. This partnership aims to accelerate the development of RNAi-based therapeutics and optimize the company's potential in the field of RNA biology. In summary, Arrowhead Pharmaceuticals is a biotechnology company specializing in RNA biology. The company has developed a patented TRiM™ technology that specifically overcomes barriers in disease therapy with RNAi-based therapeutics. Arrowhead has developed several products for the treatment of life-threatening diseases and collaborates with partners to accelerate the development of its products and optimize commercialization. Arrowhead Pharmaceuticals Inc is an innovative player in the biotechnology field and strives to improve and revolutionize the common practice of RNAi-based therapeutics. Arrowhead Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Arrowhead Pharmaceuticals SWOT Analysis

Strengths

Arrowhead Pharmaceuticals Inc has several strengths that contribute to its success:

  • Strong technological capabilities and expertise in RNA interference (RNAi) therapeutics.
  • Well-established partnerships with pharmaceutical companies.
  • Strong intellectual property portfolio with numerous patents.
  • Experienced and knowledgeable management team.
  • Successful track record in advancing drug candidates into clinical development.

Weaknesses

Despite its strengths, Arrowhead Pharmaceuticals Inc also faces certain weaknesses:

  • Reliance on limited number of drug candidates in its pipeline.
  • Dependence on external sources for funding and capital.
  • Highly competitive industry with other companies developing similar RNAi therapeutics.
  • Limited marketing and commercialization experience.
  • Vulnerability to regulatory changes and approvals.

Opportunities

Arrowhead Pharmaceuticals Inc can capitalize on the following opportunities:

  • Expanding market for RNAi therapeutics due to increased focus on targeted and personalized medicine.
  • Potential partnerships and collaborations to further advance its drug candidates.
  • Growing demand for treatments in various therapeutic areas, such as liver diseases and cancer.
  • Increasing adoption of RNAi therapeutics by pharmaceutical companies.
  • Possibility of entering new geographical markets.

Threats

Arrowhead Pharmaceuticals Inc should be mindful of the following threats:

  • Rapidly evolving and competitive nature of the biopharmaceutical industry.
  • Risks associated with clinical trials and potential failure of drug candidates.
  • Regulatory challenges and compliance requirements.
  • Fluctuations in financial and economic conditions that could affect funding and investor sentiment.
  • Emergence of alternative therapies or technologies that could disrupt the market for RNAi therapeutics.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Arrowhead Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Arrowhead Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Arrowhead Pharmaceuticals shares outstanding

The number of shares was Arrowhead Pharmaceuticals in 2023 — This indicates how many shares 106.8 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Arrowhead Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Arrowhead Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Arrowhead Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Arrowhead Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Arrowhead Pharmaceuticals stock splits

In Arrowhead Pharmaceuticals's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-1.07 -1.37  (-28.19 %)2024 Q4
6/30/2024-0.56 -1.38  (-145.25 %)2024 Q3
3/31/2024-0.17 -1.02  (-515.57 %)2024 Q2
12/31/2023-0.84 -1.24  (-48.25 %)2024 Q1
9/30/2023-0.62 -1.02  (-65.77 %)2023 Q4
6/30/2023-0.67 -0.96  (-44.12 %)2023 Q3
3/31/2023-0.65 0.45  (168.84 %)2023 Q2
12/31/20220.45 -0.39  (-187.62 %)2023 Q1
9/30/2022-0.17 -0.81  (-379.86 %)2022 Q4
6/30/2022-0.52 -0.68  (-31.81 %)2022 Q3
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Arrowhead Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

44/ 100

🌱 Environment

44

👫 Social

73

🏛️ Governance

15

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees51
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Arrowhead Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
11.41064 % BlackRock Institutional Trust Company, N.A.14,185,707323,8876/30/2024
9.80415 % The Vanguard Group, Inc.12,188,517-189,9496/30/2024
7.15001 % Avoro Capital Advisors LLC8,888,888333,3336/30/2024
5.11127 % State Street Global Advisors (US)6,354,331516,5699/30/2024
4.85047 % Fidelity Management & Research Company LLC6,030,099-309,3896/30/2024
3.32931 % Slate Path Capital LP4,139,00006/30/2024
2.98829 % Anzalone (Christopher Richard)3,715,04830,8721/31/2024
2.56547 % Invus Public Equities Advisors, LLC3,189,389152,7216/30/2024
2.36321 % Geode Capital Management, L.L.C.2,937,948183,3146/30/2024
2.05987 % T. Rowe Price Investment Management, Inc.2,560,833801,9506/30/2024
1
2
3
4
5
...
10

Arrowhead Pharmaceuticals Executives and Management Board

Dr. Christopher Anzalone

(54)
Arrowhead Pharmaceuticals President, Chief Executive Officer, Director (since 2007)
Compensation 9.92 M

Mr. Patrick O'Brien

(60)
Arrowhead Pharmaceuticals Chief Operating Officer, General Counsel, Company Secretary
Compensation 3.31 M

Mr. Kenneth Myszkowski

(57)
Arrowhead Pharmaceuticals Chief Financial Officer
Compensation 3.12 M

Dr. Javier San Martin

(58)
Arrowhead Pharmaceuticals Chief Medical Officer
Compensation 3.1 M

Mr. James Hamilton

(45)
Arrowhead Pharmaceuticals Chief of Discovery and Translational Medicine (since 2023)
Compensation 3.05 M
1
2
3

Arrowhead Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Takeda Pharmaceutical Stock
Takeda Pharmaceutical
SupplierCustomer0,30-0,58-0,19-0,83-0,03-0,22
Alnylam Pharmaceuticals Stock
Alnylam Pharmaceuticals
SupplierCustomer0,230,580,200,640,380,23
Horizon Therapeutics Stock
Horizon Therapeutics
SupplierCustomer0,030,750,220,16-0,040,24
Amgen Inc. Stock
Amgen Inc.
SupplierCustomer-0,020,520,13-0,70-0,19-0,18
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer-0,03-0,13-0,01-0,55-0,510,20
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer-0,09-0,320,07-0,38-0,61-0,62
Ebix Inc Stock
Ebix Inc
SupplierCustomer-0,300,750,09-0,010,210,61
Novartis Stock
Novartis
SupplierCustomer-0,390,190,02-0,55-0,060,01
1

Most common questions regarding Arrowhead Pharmaceuticals

What values and corporate philosophy does Arrowhead Pharmaceuticals represent?

Arrowhead Pharmaceuticals Inc represents a values-driven corporate philosophy focused on innovation, collaboration, and excellence. The company is committed to advancing RNAi therapeutics to transform the lives of patients with severe and life-threatening diseases. Arrowhead Pharmaceuticals Inc prioritizes patient-centricity, scientific integrity, and ethical practices. By leveraging its deep expertise in RNAi-based therapeutics, the company strives to deliver breakthrough treatments and improve patient outcomes. With a strong emphasis on R&D, Arrowhead Pharmaceuticals Inc demonstrates its dedication to cutting-edge research and development of innovative therapies that hold the potential to address unmet medical needs.

In which countries and regions is Arrowhead Pharmaceuticals primarily present?

Arrowhead Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Arrowhead Pharmaceuticals achieved?

Arrowhead Pharmaceuticals Inc has achieved several significant milestones. In recent years, the company has successfully completed clinical trials for its RNA interference (RNAi) therapies, demonstrating their potential in treating various diseases. Arrowhead Pharmaceuticals Inc has also entered into collaborations with major pharmaceutical companies to further develop and commercialize its RNAi therapeutics. Additionally, the company has received regulatory approvals for its investigational drugs, paving the way for potential market launches. Furthermore, Arrowhead Pharmaceuticals Inc has consistently shown promising results in preclinical and early-stage trials, highlighting the potential efficacy and safety of its innovative therapeutic approaches.

What is the history and background of the company Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals Inc is a leading biopharmaceutical company with a rich history and background. Founded in 1989, Arrowhead Pharmaceuticals has focused on developing innovative RNA interference (RNAi) therapies to treat various diseases. Over the years, the company has made significant advancements in the field of genetic medicine, utilizing its proprietary Targeted RNAi Molecule (TRiM™) platform. Arrowhead Pharmaceuticals has a robust pipeline of therapeutic candidates targeting liver, respiratory, and cardiovascular diseases, among others. With a strong commitment to research and development, the company aims to revolutionize patient care by providing effective and personalized RNAi-based therapies. Arrowhead Pharmaceuticals Inc continues to make strides in the biopharmaceutical industry, offering hope for patients worldwide.

Who are the main competitors of Arrowhead Pharmaceuticals in the market?

The main competitors of Arrowhead Pharmaceuticals Inc in the market are Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Dicerna Pharmaceuticals.

In which industries is Arrowhead Pharmaceuticals primarily active?

Arrowhead Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that develops RNA interference (RNAi) therapeutics. Their business model focuses on utilizing RNAi technology to address various diseases by silencing specific genes to target and treat specific medical conditions. Arrowhead's innovative approach in developing RNAi therapeutics has led to advancements in the treatment of liver diseases, including hepatitis B and alpha-1 antitrypsin deficiency. By leveraging their proprietary Targeted RNAi Molecule (TRiM™) platform, Arrowhead aims to provide patients with safer, more effective, and potentially curative treatment options for a broad range of diseases.

What is the P/E ratio of Arrowhead Pharmaceuticals 2024?

The Arrowhead Pharmaceuticals P/E ratio is -4.63.

What is the P/S ratio of Arrowhead Pharmaceuticals 2024?

The Arrowhead Pharmaceuticals P/S ratio is 36.37.

What is the Quality Investing of Arrowhead Pharmaceuticals?

The Quality Investing for Arrowhead Pharmaceuticals is 5/10.

What is the revenue of Arrowhead Pharmaceuticals 2024?

The expected Arrowhead Pharmaceuticals revenue is 76.43 M USD.

How high is the profit of Arrowhead Pharmaceuticals 2024?

The expected Arrowhead Pharmaceuticals profit is -600.67 M USD.

What is the business model of Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Inc is a biopharmaceutical company focused on the development of RNA interference (RNAi) and small molecule drugs. The company was founded in 2000 and is headquartered in Pasadena, California. Arrowhead Pharmaceuticals' business model includes several divisions. The company focuses on developing RNAi therapeutics for various diseases such as hepatitis B, alpha-1 antitrypsin deficiency, and cardio-metabolic disorders. RNAi is a process of highly specific silencing of certain genes involved in the cause of certain diseases. The first division of Arrowhead Pharmaceuticals is drug development. The company is developing RNAi therapeutics for the treatment of liver diseases, including hepatitis B and alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals is also developing therapeutics for cardiovascular diseases such as diabetes and obesity. The second division of Arrowhead Pharmaceuticals is collaboration with other companies. Arrowhead has made several agreements with other pharmaceutical companies. These partnerships allow Arrowhead to leverage its technology platform and products in combination with the capabilities and resources of its partners to develop better products and solutions. The third division of Arrowhead Pharmaceuticals is intellectual property (IP) management. Arrowhead has a strong IP portfolio and holds patents that protect its technology and research. The company continuously develops new technologies and improves its products to strengthen its position in the market. Arrowhead Pharmaceuticals completed its acquisition of Amgen's RNA Interference (RNAi) business on September 3, 2020, to expand and diversify Arrowhead Pharmaceuticals' RNAi portfolio by adding the talents and resources of Amgen. As part of the transaction, Arrowhead and Amgen entered into a strategic collaboration agreement in the field of RNA interference product delivery. Arrowhead Pharmaceuticals has several products on the market, including the hepatitis B drug ARO-HBV, which is in Phase 2 clinical trials and has the potential to contribute to the cure of chronic hepatitis B. The drug has been designated as an "Orphan Drug" by the US Food and Drug Administration (FDA), providing a significant opportunity to address the need for this rare disease. The company has also developed an RNAi therapeutic called ARO-AAT for the treatment of alpha-1 antitrypsin deficiency. The drug is in Phase 2 of development and potentially has the potential to increase the number of targeted patients in the coming years. Overall, Arrowhead Pharmaceuticals has a strong business model as the company focuses on a proven and scientifically based technology platform to develop effective therapeutic solutions for common and rare diseases. By partnering with other pharmaceutical companies, Arrowhead can further improve its technology and products and expand its capabilities. By managing its intellectual property, Arrowhead also ensures that its products and solutions are protected from imitation.

What is the Arrowhead Pharmaceuticals dividend?

Arrowhead Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Arrowhead Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Arrowhead Pharmaceuticals or the company does not pay out a dividend.

What is the Arrowhead Pharmaceuticals ISIN?

The ISIN of Arrowhead Pharmaceuticals is US04280A1007.

What is the Arrowhead Pharmaceuticals WKN?

The WKN of Arrowhead Pharmaceuticals is A2AGYB.

What is the Arrowhead Pharmaceuticals ticker?

The ticker of Arrowhead Pharmaceuticals is ARWR.

How much dividend does Arrowhead Pharmaceuticals pay?

Over the past 12 months, Arrowhead Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arrowhead Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Arrowhead Pharmaceuticals?

The current dividend yield of Arrowhead Pharmaceuticals is .

When does Arrowhead Pharmaceuticals pay dividends?

Arrowhead Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Arrowhead Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arrowhead Pharmaceuticals located?

Arrowhead Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Arrowhead Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arrowhead Pharmaceuticals from 11/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/30/2024.

When did Arrowhead Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/30/2024.

What was the dividend of Arrowhead Pharmaceuticals in the year 2023?

In the year 2023, Arrowhead Pharmaceuticals distributed 0 USD as dividends.

In which currency does Arrowhead Pharmaceuticals pay out the dividend?

The dividends of Arrowhead Pharmaceuticals are distributed in USD.

All fundamentals about Arrowhead Pharmaceuticals

Our stock analysis for Arrowhead Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arrowhead Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.